NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
VelocityShares Daily Inverse VIX Medium Term Exchange Traded Notes (ZIV)
Class Period: June 30, 2017 - February 5, 2018
Lead Plaintiff Deadline: April 5, 2019
Join the action: https://www.zlk.com/pslra-1/velocityshares-daily-inverse-vix-medium-term-exchange-traded-notes-loss-form?wire=3
The filed complaint alleges that throughout the class period defendants made materially false or misleading statements relating to the risks of investing in ZIV including that: (i) the inverse ETNs was not appropriate for managing daily trading risks; (ii) Credit Suisse had designed the ZIV to fail under certain market conditions; (iii) Credit Suisse had offered and sold more inverse ETNs than the market could bear, which would enable Credit Suisse to cause the collapse of the inverse ETNs when the opportunity presented itself; and (iv) Credit Suisse could actively manipulate inverse ETNs by precipitating an acute liquidity event in volatility markets including markets for VIX futures.
To learn more about the VelocityShares Daily Inverse VIX Medium Term Exchange Traded Notes class action contact email@example.com.
Corcept Therapeutics Incorporated (CORT)
Class Period: August 2, 2017 - February 5, 2019
Lead Plaintiff Deadline: May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corcept-therapeutics-incorporated-loss-form?wire=3
The lawsuit alleges: Corcept Therapeutics Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company’s sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis
To learn more about the Corcept Therapeutics Incorporated class action contact firstname.lastname@example.org.
General Electric Company (GE)
Class Period: December 27, 2017 - October 29, 2018
Lead Plaintiff Deadline: April 2, 2019
Join the action: https://www.zlk.com/pslra-1/general-electric-company-loss-form?wire=3
The lawsuit alleges: General Electric Company made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the design and technology of GE Power’s flagship gas turbines were structurally flawed as they were plagued with an oxidation problem that caused the blades in the H-Class gas turbines to fail; (ii) GE Power’s goodwill was materially overstated, in large part because of such structural issues; (iii) the Company lacked adequate internal and financial controls; and (iv) as a result of the foregoing, Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis.
To learn more about the General Electric Company class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: